Study of a Cohort of Non-HIV Immunocompromised Patients With Toxoplasmosis at the Strasbourg University Hospital

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-02-02

Study Completion Date

2026-02-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Toxoplasmosis in HIV-positive individuals is well-studied and has a codified management protocol, which is not the case for other immunodeficiencies, except for recent recommendations in the context of hematopoietic stem cell transplantation. A description of this population is necessary to estimate the number of patients affected and to define their specific management (diagnosis, treatment, prevention).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cerebral Toxoplasmosis and AIDS

NCT00803621

Cerebral Toxoplasmosis AIDS

COMPLETED

Isolated Positive Toxoplasma Gondii PCR in Blood

NCT07054918

Toxoplasmosis

NOT_YET_RECRUITING

Analysis of Cerebrospinal Fluid in Patients With Cerebral Toxoplasmosis at CHSD (2004-2024)

NCT07044037

Toxoplasmosis, Cerebral Toxoplasmosis Meningitis +3 more

COMPLETED

Pregnancy and Congenital Toxoplasmosis

NCT05774496

Congenital Toxoplasmosis Retinochoroiditis

COMPLETED

New Diagnostic Approach for Congenital Toxoplasmosis

NCT03385499

Congenital Toxoplasmosis

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cerebral Toxoplasmosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult (≥18 years)
* Immunocompromised (i.e., solid organ transplant recipient, hematological malignancy, cancer patient, patient treated with immunosuppressive therapy or therapy affecting the immune system by any mechanism, hematopoietic stem cell transplant recipient, patient with an autoimmune disease or immunodeficiency, whether primary or secondary).
* At least one positive toxoplasmosis PCR test (regardless of tissue)

Exclusion Criteria

* Subject who has expressed opposition to the reuse of their data for scientific research.
* HIV positive
* Congenital toxoplasmosis
* Isolated ocular toxoplasmosis in immunocompetent individuals

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No